do glp-1 agonists have cardiovascular benefit The Benefits of Therapy: Beyond Weight Loss do glp 1 agonists have

2026 Mousai Wellness Center

For those who do not achieve glycemic targets with lifestyle therapy, metformin, and SGLT2i, or who cannot tolerate these agents, whether due to adverse events or because other restrictions apply, other medications are recommended

The choice will depend on patient preference for oral versus injectable administration, the importance of cardiovascular outcomes data, and the weight loss goals of the individual patient

In type 2 diabetes trials (the SUSTAIN program), Ozempic produced an average weight loss of around 4.5 kg to 6.5 kg (roughly 10 to 14 lbs) over 52 weeks, depending on the dose

This is the same basic threshold used for GLP-1 weight loss medications

As pharmacological interventions demonstrate robust efficacy, obesity is increasingly recognized as a medical condition warranting comprehensive treatment, akin to other chronic diseases